References
- Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 2019; 104: 1702–1709. doi: 10.3324/haematol.2019.221093.
- Melchiorre D, Linari S, Manetti M, et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica 2016; 101: 219–25. doi: 10.3324/haematol.2015.133462.
- Kihlberg K, Baghaei F, Bruzelius M, et al. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study. Haemophilia 2021; 27(3): 366–374. doi: 10.1111/hae.14299.
- Shih MY, Wang JD, Yin JD, et al. Differences in major bleeding events between patients with severe hemophilia A and hemophilia B: a nationwide, population-based cohort study. Clin Appl Thromb Hemost 2019; 25: 1076029619888023. doi: 10.1177/1076029619888023.
- Dolan G, Benson G, Duffy A, et al. Haemophilia B: Where are we now and what does the future hold? Blood Rev 2018; 32(1): 52–60. doi: 10.1016/j.blre.2017.08.007.
- Clausen N, Petrini P, Claeyssens-Donadel S et al; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia 2014; 20: 747–55. doi: 10.1111/hae.12470.
- Osooli M, Steen Carlsson K, Astermark J, et al. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience. Haemophilia 2017; 23(5): e403–e408. doi: 10.1111/hae.13302.
- Alprolix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (accessed 27 August 2021).
- Idelvion Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 27 August 2021).
- Refixia Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (accesed 27 August 2021).
- Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost 2017; 117(6): 1023–1030. doi: 10.1160/TH16-12-0942.
- Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118(10): 2695–701. doi: 10.1182/blood-2011-02-335596.
- Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120(12): 2405–11. doi: 10.1182/blood-2012-05-429688.
- Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med 2018; 9: 135–140. doi: 10.2147/JBM.S159297.
- Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv 2021; 5(1): 279. doi: 10.1182/bloodadvances.2019001140.
- Kahneman D, Tversky A. Judgement under uncertainty: heuristics and biases. Science 1974; 185: 1124–1131. doi: 10.1126/science.185.4157.1124.
- Tversky A, Kahneman D. Availability: A heuristic for judging frequency and probability. Cognitive Psychology 1973; 5: 207–232. doi: 10.1016/0010-0285(73)90033-9.
- Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046.
- Mansouritorghabeh H, Mohades ST. Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review. Cardiovasc Hematol Disord Drug Targets 2020; 20(3): 185–190. doi: 10.2174/1871529X20666200701104143.
- Rendo P, Smith L, Lee HY, et al. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis 2015; 26(8): 912–8. doi: 10.1097/MBC.0000000000000359.
- Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol 2018; 9(11): 335–346. doi: 10.1177/2040620718802606.
- Pollard D, Harrison C, Dodgson S, et al. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–630. doi: 10.1111/hae.14002.
- O'Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia 2015; 21(4): 436–43. doi: 10.1111/hae.12720.
- Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169.
- Garner K, Guelcher C, Pollard D. The use of rIX-FP in patients with haemophilia B: A nurse's perspective. J Haem Pract 2021; 8(1): 86–97. doi: 10.17225/jhp00180.
- Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178.
- Buckner TW, Sidonio R Jr, Witkop M, et al. Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 299–314. doi: 10.2147/PROM.S219166.
- Cutter S, Guelcher C, Hunter S, et al. Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study. Patient Relat Outcome Meas 2019; 10: 257–266. doi: 10.2147/PROM.S214188.
- Blamey G, Buranahirun C, Buzzi A, et al. Hemophilia and sexual health: results from the HERO and B-HERO-S studies. Patient Relat Outcome Meas 2019; 10: 243–255. doi: 10.2147/PROM.S211339.
- Buckner TW, Witkop M, Guelcher C, et al. Impact of hemophilia B on quality of life in affected men, women, and caregivers – Assessment of patient-reported outcomes in the B-HERO-S study. Eur J Haematol 2018; 100(6): 592–602. doi: 10.1111/ejh.13055.
- Benefix Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (accessed 27 August 2021).
- Rixubis Summary of Product Characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/rixubis-epar-product-information_en.pdf (accessed 27 August 2021).